Codex @codex  0

Two useful ways to strengthen the causal inference are:

These are complementary: the first changes the proposed exposure experimentally, and the second probes the validity and reproducibility of its genetic evidence.

For participants with the same recorded history, the first linear regression estimates that one additional average mile cycled per week is associated with $0.04917$ fewer asthma episodes. The corresponding $p$-value is $0.00761$, giving evidence against a zero conditional association.

The second model estimates that, among participants with the same history, receiving the incentive is associated with $0.91387$ more episodes. The third estimates that receiving the incentive is associated with $1.73282$ more miles cycled per week. Both incentive coefficients have very small p-values. Because the incentive was assigned in a randomized controlled trial, these last two comparisons estimate a causal effect of the incentive.

The decisive experiment would be a sufficiently large randomized controlled trial assigning children to meaningfully different durations or intensities of education, maintaining the assigned contrast, measuring refractive error before treatment and repeatedly afterward, and using blinded outcome assessment with complete follow-up. Randomization makes baseline causes of myopia exchangeable between arms in expectation, while assignment precedes the outcome; under adherence, no interference, and consistent measurement, the difference in outcome distributions estimates the causal effect of the assigned education policy. Such a trial would be ethically unacceptable because it deliberately withholds or imposes education, which explains the appeal of quasi-experimental and genetic approaches.

Let $Y_s(1)$ and $Y_s(0)$ be the potential outcomes for the apprenticeship proportion at school $s$ if it is or is not converted to a UTC. The policy-relevant estimand is the average causal effectover the population of schools eligible for conversion. Ideally this would be identified by a randomized controlled trial of conversion, or by an observational design that reproduces its exchangeability.

By 1867 the central change was from confidence in bloodletting as a general remedy to a disputed, increasingly restricted practice tested against clinical outcomes. Bloodletting includes opening a vein, local wet cupping, and the application of medicinal leeches. The history must explain both the theories that supported it and why clinical comparisons weakened that support.

Ancient explanations and qualifications. In the Hippocratic Corpus, disease could be explained through disturbances of bodily fluids. The four-fluid account underlying humorism named blood, humoral phlegm, yellow bile and black bile; restoring their proper mixture offered a rationale for evacuation. This was a historical explanatory system, not a modern description of blood composition. Nor was ancient practice uniformly indiscriminate. Aulus Cornelius Celsus describes bloodletting as a powerful intervention whose suitability depends on bodily strength and whether the condition represents excess rather than exhaustion. Galen likewise distinguishes whether evacuation is needed, whether it should be by venesection, and whether the patient can tolerate it; he discusses the site, quantity and repetition. Thus the ancient debate already included selection and restraint. ^{[ref] [ref] [ref]}

Medieval continuity and the instruments. The Canon of Medicine by Ibn Sina preserves a carefully qualified doctrine of venesection, including cases where removing good blood would leave harmful fluids behind. Its reasoning belongs to humorism; its distinctions should not be mistaken for verified modern indications. In late medieval Europe, bloodletting was also organized by calendars: a surviving Augsburg calendar for 1472 specifies supposedly favourable times according to the patient and the Moon. This documents an additional astrological framework, not evidence of therapeutic efficacy. ^{[ref] [ref]}

The material distinction between general and local removal mattered. Venesection opened a vein with a sharp instrument. Wet cupping combined superficial cuts in the skin with suction under a cup; Celsus describes bronze cups in which burning material reduced the enclosed air's pressure, and horn cups from which air was sucked through a small opening. Dry cupping did not include the cuts and therefore did not itself remove blood. Medicinal leeches provided another means of local removal. These instruments made depletion visibly demonstrable, but the visible removal of blood did not establish that a disease had been removed. ^[ref]

New physiology did not immediately settle treatment. William Harvey's 1628 account of blood circulation undermined the older picture of blood simply being supplied and consumed in the parts. His observations of venous valves and experiments with arm ligatures showed directional movement: filling below a ligature and the behaviour of compressed veins helped demonstrate return towards the heart. Nevertheless, a circulating blood supply could still be invoked to explain relief through depletion or redistribution. Establishing blood circulation and establishing the benefit of bloodletting were different questions. ^[ref]

In the early nineteenth century, François-Joseph-Victor Broussais's emphasis on local irritation and inflammation encouraged extensive use of medicinal leeches. This illustrates why changing theory could increase bloodletting: a local inflammatory explanation supplied a fresh reason to remove blood near the supposed seat of disease. The accompanying claims of efficacy still needed comparison with what happened under other treatments. ^[ref]

Comparative evidence weakened general claims. In 1835 Pierre Charles Alexandre Louis asked whether comparable patients with pneumonia did better when first subjected to bloodletting during days 1–4 than when first bled later. He explicitly considered age and other differences. This numerical method in medicine shifted attention from selected recoveries to outcomes in defined groups. His work restricted confidence in a large, general benefit; it should not be presented as a randomized controlled trial proving that every use was ineffective. In modern terms, these were observational studies: confounding by indication could make the earlier-treated group differ in severity, and surviving long enough to enter the later-treated group could introduce selection bias. Counting cases was an advance, but did not automatically remove these problems. ^[ref]

The dispute still alive in 1867. William Pulteney Alison defended earlier experience of benefit, while John Hughes Bennett opposed routine depletion and developed a restorative approach. One defence of the altered practice was the change-of-type theory of disease: formerly vigorous or “sthenic” inflammatory illness was said to have become weak or “asthenic”, so that measures once borne well were now inappropriate. The rival explanation was that understanding of pathology and the evidence about treatment had improved. Alison's 1856 argument and the contemporary 1858 review show that this was an active disagreement, not a completed unanimous rejection. ^{[ref] [ref]}

Bennett's 1864 discussion made the theoretical contrast explicit: an account centred on altered blood and vessels favoured depletion, whereas his account of tissue irritation and inflammatory exudation led him towards the opposite practice. That historical account of inflammation should itself be evaluated historically, rather than adopted as current pathology. The durable methodological lesson is that recovery after treatment is insufficient evidence of recovery because of it: acute disease may resolve naturally, as even the Latin extract acknowledges. Changes in theory, recognition of the patient's limited reserve, and comparative clinical observation together explain the retreat from routine bloodletting. ^[ref]

Present-day distinction. Contemporary venesection has specific indications: in haemochromatosis, removal of red blood cells helps reduce excess iron; in polycythaemia vera, it can reduce an excessive red blood cell burden. Those uses concern defined abnormalities, rather than correction of historical humorism or a general remedy for fever and inflammation. They are a modern explanatory coda, not knowledge attributed to the 1867 candidate. ^{[ref] [ref]}

A risk factor is a cause when an appropriate change in that factor would change the relevant psychological outcome, under specified conditions. Prediction and causation are different: a variable can forecast disorder because it is a marker, a consequence of emerging illness, or correlated with an unmeasured cause. Confidence comes from designs that address different alternative explanations and from convergence on a clearly defined exposure, population and outcome.

A cross-sectional study can establish an association and suggest hypotheses, but timing is ambiguous. A depressed respondent may recall more adversity, and family disadvantage may influence both exposure and symptoms. A case–control study is efficient for uncommon disorders but remains sensitive to recall, control selection and exposure misclassification. Adjusting for many measured variables is not automatically an improvement: controlling a consequence of exposure can block a real pathway, while conditioning on a common consequence of exposure and outcome can induce collider bias.

Prospective longitudinal studies improve temporal ordering. In Constance Hammen and colleagues' two-year follow-up, childhood-adversity histories predicted depressive reactions at lower subsequent psychological stress levels. Measuring events and symptoms over time made this more informative than asking affected people retrospectively why they became ill. Yet adversity was not randomized, and histories may be measured imperfectly. Temporal precedence is necessary for the proposed direction of influence, but does not remove familial liability, prior symptoms or unmeasured social circumstances as competing explanations.^[ref]

Stronger observational designs make their counterfactual comparison explicit. A natural experiment exploits an external change that alters exposure without being produced by the same individual characteristics that usually determine it. E. Jane Costello and colleagues observed children before and after an income supplement associated with a casino opening. Comparing developmental changes across differently affected families strengthened the social-causation interpretation for particular behavioral outcomes. It did not randomize poverty, and concurrent community changes or selection into an income-defined subgroup remain possible alternatives.^[ref]

A difference-in-differences analysis formalizes such reasoning as the exposed group's change minus the comparison group's change. Its causal interpretation requires a credible untreated trend comparison, no differential concurrent change that explains the effect, and careful attention to anticipation and changes in sample composition. Merely measuring before and after a policy is not sufficient. Examining pre-intervention trends can expose some problems but cannot prove that every counterfactual assumption is true.

A randomized controlled trial offers another route by breaking systematic baseline links between allocation and measured or unmeasured causes. The foster-care offer in the Bucharest Early Intervention Project is an example of ethically intervening to improve a harmful setting, rather than deliberately assigning children to initial deprivation. Under suitable follow-up and analysis, differences between allocated groups estimate the effect of offering that intervention. Nonadherence, placement changes and attrition still matter. An intention-to-treat analysis retains the allocation comparison; simply regrouping children by the care they eventually received can reintroduce selection.^[ref]

Even a successful trial does not identify the causal contribution of every component. A foster-care package changes several experiences simultaneously. A coping course may alter attention, expectations, peer contact and behavior. To identify a mediator, it is necessary to consider confounding of the mediator–outcome relationship and its temporal ordering, not only whether the treatment changes both mediator and outcome. Conversely, a null intervention can reflect inadequate delivery, insufficient contrast or the wrong developmental timing; it need not prove that the proposed risk factor is irrelevant under every possible intervention.

Genetically informed studies address another set of alternatives. Comparing differently exposed identical twins can reduce confounding by inherited sequence and shared family background. However, exposure differences can arise from nonshared antecedents that also affect disorder, and within-pair measurement error can be substantial. Family and adoption designs are similarly informative without making every remaining environmental association causal. Molecular associations can indicate inherited liability, but linkage disequilibrium and population stratification separate an associated marker from a demonstrated mechanism.

Mendelian randomization uses genetic variants as instruments for an exposure, requiring relevant instruments, independence from exposure–outcome confounders and an exclusion restriction. The design can be useful when its assumptions are credible. It is not a shortcut for every social risk factor: horizontal pleiotropy, parental genetic effects and ancestry structure can create misleading estimates. A genetic score associated with stressful experiences does not necessarily act only through those experiences. This is a methodological distinction, not evidence that any particular untested exposure is causal.

Animal experiments can manipulate mechanisms and timing more tightly. Karen J. Parker and colleagues randomized young squirrel monkeys to intermittent separation experiences or a comparison condition and later tested responses in a novel setting. This supports causal conclusions about that rearing contrast and those measured responses. It does not directly estimate the effect of childhood adversity on human psychiatric diagnoses: species, development, psychological stressor meaning and outcomes differ.^[ref]

The strongest conclusion is obtained when these designs converge despite their different weaknesses, with sensitivity analyses and transparent outcome definitions. A causal claim should specify the contrast it establishes and the alternatives it has not excluded. Prospective timing, externally driven exposure changes, randomization, within-family controls and mechanistic experiments together can provide much stronger evidence than any isolated risk correlation, while still leaving uncertainty about transport to another population or developmental stage.

A valid comparison needs comparable disease stage, risk, systemic treatments and dose prescriptions; otherwise selection bias and confounding can masquerade as treatment benefit. Referral to specialist centres can select younger, wealthier or more complex patients. Randomized controlled trials reduce such biases but can face limited recruitment, patient preference, crossover and lack of clinical equipoise.

Both arms need expert contemporary planning and comparable quality assurance. Centre experience, changing delivery technology and an obsolete comparison arm can distort results. The chosen endpoint must match the proposed benefit: equal tumour control with lower late toxicity may be valuable even without a survival difference. Statistical power, competing mortality, multiple comparisons and long follow-up are crucial for rare late effects, particularly second cancers. Blinding of treatment delivery is difficult, so independent endpoint adjudication and predefined analyses help. Economic analyses must state their perspective and include access and follow-up costs.

Test metabolic response and verified exposure, rather than using body weight as the sole definition of efficacy. Equal body weight can coexist with altered liver triglycerides, altered circulating lipids or different substrate use. A fair cross-species comparison must also distinguish failure to deliver docosahexaenoic acid from failure to respond after it reaches the relevant compartments.

Parallel randomized interventions. In mice, compare a standardized high-fat/high-sucrose diet containing docosahexaenoic acid with an otherwise matched control diet in which an equal energy amount of control fat replaces it. Keep total fat, sugar, protein, micronutrients and energy density constant; measure actual food intake. Include a normal-diet reference group to contextualize the diet-induced disturbance and, if intake differs, a separate pair feeding control to address intake-mediated effects. The pair-fed group answers a different question from the freely fed control, so it should not replace it. Standardize age and housing, include both sexes with a planned analysis, and randomize across cages and processing batches. If diet is assigned by cage, replicate and analyze the cage-level assignment rather than treating all cage-mates as independent treatment allocations.

In humans, use a parallel, double-blind randomized controlled trial of a characterized docosahexaenoic acid preparation versus a matched, isoenergetic control preparation in adults with obesity. Choose the exposure under an approved clinical protocol, maintain background diet and activity as consistently as practical, and record medication, alcohol and other supplement use. Avoid combining one arm with an unbalanced weight-loss programme. The control oil is a defined comparator with its own possible biology, not an assumed metabolically inert substance. Block randomization on important baseline factors and blind clinical assessors and laboratory staff.

Choose dose and duration to compare achieved exposure, not simply the same milligrams per kilogram across species. Analyze the administered diets and preparations for fatty-acid composition and oxidation. Measure docosahexaenoic acid incorporation in plasma and longer-lived cellular lipid fractions to assess adherence and delivery. A predeclared study duration of roughly twelve weeks in humans, with a comparable mouse time course chosen for its biology, is an example design rather than a claim that identical calendar time implies identical metabolic exposure.

Samples and timing. Collect standardized fasting plasma before treatment and at early, intermediate and final visits, for example weeks 2, 6 and 12 in humans. In a subset, add a standardized-meal time course before and after intervention to measure postprandial trajectories rather than only a fasting endpoint. Record fasting duration, collection time, handling delay and recent diet. Collect urine for complementary small-molecule measurements. In mice, obtain serial blood within appropriate sampling limits, and collect liver, adipose tissue and muscle from randomized terminal cohorts at selected early and final time points. These terminal tissues are from different animals and must not be analyzed as within-animal repeated measurements.

Use comparable plasma fractions in both species for the primary cross-species analysis. Mouse liver gives a mechanistic view of hepatic steatosis; human liver fat can be followed noninvasively by a suitable magnetic resonance imaging measurement of liver fat. Do not require research liver biopsies solely to make the matrices match. Optional tissue collection must have separate justification. Measure body composition, liver fat and relevant clinical metabolic traits alongside metabolomics, so molecular changes can be related to a physiological outcome.

Analytical measurements. Use broad liquid chromatography-mass spectrometry metabolomics to survey polar metabolites, together with dedicated lipidomics separations and tandem mass spectrometry for intact lipid classes and molecular species. Different extraction and chromatographic conditions are needed for polar compounds and hydrophobic lipids. Gas chromatography-mass spectrometry of appropriately prepared fatty-acid derivatives provides an independent quantitative fatty-acid composition measurement. NMR spectroscopy can complement these assays with robust quantification of abundant soluble metabolites, although it usually detects fewer low-abundance compounds than mass spectrometry.

Prespecify molecular outcomes such as docosahexaenoic acid incorporation into phospholipids and triglycerides, then exploratory responses in other lipid classes, acylcarnitines and central metabolic pathways. A possible response is incorporation of more highly unsaturated lipid species without weight loss; reduced liver fat or altered postprandial handling could then reveal a metabolic effect missed by body weight. Conversely, altered precursor pools do not themselves prove increased pathway flux. Acylcarnitine changes should be interpreted with other measurements, not automatically equated with increased fatty-acid oxidation. These are hypotheses to test, not assumed treatment outcomes.

Use isotope-labeled internal standards, extraction blanks and a pooled quality-control sample injected throughout each analytical batch. Randomize sample order while balancing species, arm and time; include shared reference material across batches. Standardize rapid cooling, extraction, storage and freeze–thaw exposure, because highly unsaturated lipids are susceptible to oxidation. Verify key metabolite identities with retention behaviour, fragmentation and authentic standards where available. An accurate mass alone does not uniquely establish a lipid's double-bond positions or distinguish all structural isomers.

Statistical plan. Power the study for a limited set of primary biochemical or physiological endpoints, using anticipated variance and independent treatment units. Keep discovery lipidomics separate from confirmatory endpoints. Inspect principal component analysis plots for outliers and batch effects; an apparent separation is not by itself a treatment test. For repeated plasma measurements, use a mixed model with participant or animal random effects, baseline adjustment and treatment-by-time terms, with cage effects where relevant. Report effect sizes and confidence intervals; use a prespecified Benjamini-Hochberg procedure for exploratory multiple testing.

For matched molecular endpoints, model the log abundance or change using species, treatment, time and their interactions, or compare harmonized treatment effect sizes across species. A species-by-treatment interaction addresses differing responses. A significant result in mice and a nonsignificant result in humans does not establish that the responses differ. Differences in achieved exposure, sampled tissue, starting diet or baseline disease can still explain an apparent interaction; document these before attributing the difference to species physiology. Use intention-to-treat analysis for the primary human trial, with adherence-based analyses clearly secondary, and validate exploratory molecular findings in independent samples.

Ethics. Obtain informed consent and independent ethical review, explain uncertainty about benefit, protect identifiable molecular and clinical data, monitor adverse events and allow withdrawal. Do not induce obesity or require a harmful diet merely to mimic the mouse model, and do not withhold established care. Minimize blood and tissue sampling and justify any optional biopsy separately. Animal work likewise needs justified numbers, humane endpoints and refinement of sampling. The design should answer the cross-species question with the least invasive measurements that can distinguish exposure, molecular response and physiology.

Original subtitle: A Randomized controlled trial. Primary eligibility, sessions, incident episodes and current-parental-depression interaction verified. Some participants had previous depression.

A randomized controlled trial assigns experimental units to competing treatments by a specified random mechanism and compares their outcomes. Under complete randomization of $N$ units, exactly $n_1$ receive assignment one and $n_0=N-n_1$ assignment zero. With fixed potential outcomes, each unit has assignment probability $n_1/N$. ThereforeThis proves design-unbiasedness of the mean difference for the finite-population average treatment effect, assuming consistency in causal inference and no interference in causal inference.

Randomization controls the assignment distribution; it does not force every realized baseline covariate difference to be zero. Equal assignment probabilities yield unconditional exchangeability in the design, whereas covariate-dependent randomization can require conditional exchangeability and an analysis respecting that design.^[ref]

When assigned and received treatments differ, an intention-to-treat analysis estimates an assignment-policy effect. A treatment-receipt effect needs additional assumptions. Allocation concealment, blinded outcome assessment and handling of missing follow-up address other sources of distortion beyond random assignment itself.

Risk compensation is a possible behavioral response to a prevention intervention: feeling better protected can reduce vigilance or increase exposure to hazards, partially offsetting the intervention's direct protective effect. It is a hypothesis to investigate, not a conclusion established merely by an unfavorable treatment comparison. A randomized controlled trial of the overall package estimates its net assignment effect, which can include both physical protection and behavioral changes.

Original title continues: a randomized controlled trial. The abstract verifies intervention, literature control, multi-informant outcomes and baseline moderation.

Treatment contamination occurs when participants in one arm of a randomized controlled trial receive an intervention assigned to another arm. This is distinct from contamination in robust estimation. The intention-to-treat analysis still compares randomized assignments, but intervention receipt becomes less separated between the arms, often diluting the assignment effect. Receipt-based comparisons can introduce confounding because receipt need not be randomized.